NCT01977625

LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women

Utilizing fMRI to Determine the Effects of Vyvanse® on Memory, Attention, and Brain Activity in Menopausal Women

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: University of Pennsylvania · Academic / Other
• Sex: Female
• Age: 45 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This study seeks to assess the effects of lisdexamfetamine (trademark name: Vyvanse; LDX) on executive function and prefrontal cortex activation in menopausal women ages 45-57, who report subjective cognitive difficulties. This protocol will recruit women from Dr. Epperson's ongoing study, Protocol #812470, to examine the impact of LDX on brain activation during performance of cognitive tasks specifically probing prefrontal cortex function.

Conditions

• Menopause
• Brain Activity
• Cognition

Interventions

Type	Name	Description
DRUG	Lisdexamfetamine	The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
OTHER	Placebo	To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.

Timeline

• Start date: 2011-12-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2013-11-06
• Last updated: 2018-07-27
• Results posted: 2017-07-11

Locations

1 site across 1 country: United States